Other GCC Countries Autoinjectors Market Overview

The Other GCC Countries Autoinjectors Market — Qatar, Kuwait, Bahrain and Oman — was valued at USD 60.02 Million in 2025 and is projected to reach USD 194.84 Million by 2035, growing at a CAGR of 12.50%, up from USD 39.36 Million in 2020. The grouping ranks fifth in the Middle East & Africa Autoinjectors Market report with an 11.6% regional share and grows broadly in line with the regional 12.53%, with revenue expanding roughly 3.2× over the forecast decade.

The Global Autoinjectors Market report describes these four markets in one sentence: they share Saudi Arabia's centralised procurement pattern at smaller scale, with growth tracking government health-investment programmes. Each is a high-income, government-funded health system in which a single national purchaser — Qatar's Ministry of Public Health and Hamad Medical Corporation, Kuwait's Ministry of Health, Bahrain's NHRA with the Ministry of Health, Oman's Ministry of Health — registers, lists and tenders for the majority of the population, so formulary and tender decisions move national volume in single steps. Combined with some of the world's highest diabetes and obesity prevalence rates, small populations and premium per-capita spending, the four markets behave like miniature versions of the Kingdom, supplied largely through the United Arab Emirates's free-zone re-export hub. This report quantifies the grouping across twelve segmentation axes and 27 segment tables with a dedicated four-country analysis.

What Shapes the Other GCC Markets

1. Single-buyer procurement at national scale. In each of the four countries, one ministry or one flagship hospital corporation buys for most residents, so a listing decision for a GLP-1, a biologic or a biosimilar presentation — and therefore its autoinjector — is a national step-change. The report reads this as the regional analogue of the single-buyer dynamics it analyses for government preparedness segments, and treats government health-investment programmes (Qatar's and Kuwait's hospital build-outs, Oman's Vision-linked health reform, Bahrain's national insurance rollout) as the demand floor. Suppliers win with SFDA-aligned dossiers — SFDA approvals are widely referenced across the GCC — reliable global capacity and cold-chain logistics through Dubai.

2. Diabetes and obesity at the top of the global range. Qatar, Kuwait, Bahrain and Oman carry some of the highest diabetes and obesity prevalence rates in the world — the IDF Diabetes Atlas places the Middle East and North Africa among the fastest-growing prevalence regions to 2050 — so insulin and GLP-1 demand is the volume engine. Therapeutic peptides and proteins reach USD 344.79 Million across MEA by 2035 at 12.84% CAGR, faster than the regional market, and GLP-1 receptor agonists on the WHO Essential Medicines List support formulary inclusion.

3. Premium adoption in small, wealthy, expatriate-heavy populations. High per-capita spending, mandatory or expanding health insurance for expatriate workforces and digitally engaged populations make the four markets early adopters of connected devices (Ypsomed SmartPilot as the report's reference; integrated connectivity grows at 13.82% CAGR across MEA), reusable platforms (13.62%) and large-volume on-body systems — the SFDA's December 2025 approval of the enFuse-based EMPAVELI Injector is the Gulf reference. Biosimilars from Teva, Celltrion, Samsung Bioepis, Fresenius Kabi and the Indian majors compete on device experience in national tenders.

Other GCC Countries Autoinjectors Market by Country — In-Depth Analysis

The four markets share the Gulf procurement model but differ in scale, insurance structure and health-system maturity. The country view reads each against the report's drivers.

How the country analysis is used in the report. The four-country view maps the grouping's revenue lines from the 27 segment tables onto single-buyer procurement, insurance rollout, diabetes prevalence and Dubai-routed logistics, so that a device maker can see where national tenders decide share, a biosimilar company where reliance pathways (NHRA) shorten entry, and a pharma partner where each modality's prescribing base sits. Quantified sub-regional revenue splits (by country, or by government/private channel) are available as a customization of this report — request the country data cut here.

Other GCC Countries Segment Insights

Growth rates shown are the Middle East & Africa values from the report's regional segment tables; the grouping's own trajectory (12.50%) tracks them almost exactly, as the report notes. The four markets' distinctive mix is their diabetes-driven peptide weighting, their single-buyer structure and their premium-feature adoption in small, wealthy populations.

Market Drivers and Restraints in the Other GCC Countries

• Driver — government health-investment programmes. Hospital build-outs, national-insurance rollouts (Sehati, Dhamani, Qatar's expatriate scheme) and Vision-linked reforms — the report's stated growth driver for the grouping.
• Driver — single-buyer procurement. One ministry or hospital corporation per country moves national volume in a step; SFDA-aligned dossiers and NHRA reliance pathways shorten entry.
• Driver — diabetes and obesity burden. Among the world's highest prevalence rates; GLP-1s on the WHO Essential Medicines List; Novo Nordisk's capacity programme and Nemera's GLP-1 expansion serve Gulf demand.
• Driver — biosimilar and global platform supply via Dubai. Teva, Celltrion, Samsung Bioepis, Fresenius Kabi; platforms from SHL Medical, Ypsomed, Owen Mumford, Gerresheimer and Haselmeier; Enable Injections on-body systems referenced from the SFDA approval.
• Restraint — small populations and tender price compression. Limited absolute volume; single-buyer tendering confines premium presentations to insured groups.
• Restraint — four separate registrations. Despite GCC coordination, each national regulator requires its own dossier, multiplying qualification cost for a single presentation.
• Restraint — import dependence and substitution. No local device manufacturing; oral GLP-1s and needle-free epinephrine modelled as substitutes; counterfeit GLP-1 pens seized in the U.S. supply chain (FDA) raise the serialisation bar for Gulf importers.

Competitive Landscape

The four markets are served by multinational platform users headquartered for the region in Dubai and Riyadh — Novo Nordisk, Eli Lilly, Sanofi, AbbVie, Pfizer, AstraZeneca, Johnson & Johnson and UCB — and by biosimilar and generic suppliers (Teva, Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, Lupin, Sun Pharma, Biocon Biologics) that win national tenders on price and device experience. Devices come from SHL Medical, Ypsomed, Owen Mumford / embecta, Gerresheimer, Haselmeier, Nemera, Elcam and Kindeva, with Enable Injections, BD, West Pharmaceutical Services, SCHOTT Pharma, Nipro and Terumo anchoring on-body systems and primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — Other GCC Countries

Key Questions Answered

• How large is the Other GCC Countries autoinjectors market and how does each of Qatar, Kuwait, Bahrain and Oman contribute to 2035?
• How does single-buyer procurement in each country move national autoinjector volume in steps, and which suppliers win those tenders?
• How do national-insurance rollouts and hospital build-outs — the government health-investment programmes the report identifies — convert into device demand?
• How do NHRA reliance pathways, SFDA-aligned dossiers and Dubai-routed logistics shorten entry into the four markets?
• Which platform specialists, biosimilar suppliers and primary-container makers are best positioned in the Gulf's smaller single-buyer markets?

This sub-regional report is drawn from the Global Autoinjectors Market report. Related coverage: Middle East & Africa Autoinjectors Market report, Saudi Arabia, United Arab Emirates, North America, United States, Canada, Mexico, Europe, Germany, United Kingdom, France, Italy, Spain, Benelux, Switzerland & Austria, Nordic Countries, Central & Eastern Europe, Asia-Pacific, China, Japan, South Korea, India, Australia & New Zealand, Southeast Asia, Latin America, Brazil, Argentina, Colombia and Chile autoinjectors market reports.